TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10228142

Group type: EXPERIMENTAL
Intervention: Salbutamol via Turbuhaler (100 microgram per inhalation)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Salbutamol via pMDI (100 microgram per inhalation)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Salbutamol via either device (pMDI or Turbuhaler)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Salbutamol via pMDI and Turbuhaler
Number of subjects: 22
Study: 8568123

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide, 2.4 mg/day, administered through a pressurized metered-dose inhaler for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as no treatment or placebo during the study)
Number of subjects: 20
Study: 1648976

Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted platelets plus CMV-seronegative red blood cells
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard unscreened blood products
Number of subjects: 77
Study: 4043476

Group type: EXPERIMENTAL
Intervention: Combined UVB-UVA treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: UVB therapy alone
Number of subjects: 56
Study: 30225878

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1767

Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 1767
Study: 27710240

Group type: EXPERIMENTAL
Intervention: Coupled group (higher P/O)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Uncoupled group (lower P/O)
Number of subjects: 47
Study: 24154932

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily and low-fat diet
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-fat diet only
Number of subjects: 79
Study: 22595156

Group type: EXPERIMENTAL
Intervention: Axial scan protocol
Number of subjects: 400

Group type: COMPARATOR
Intervention: Helical scan protocol
Number of subjects: 400
Study: 20177294

Group type: EXPERIMENTAL
Intervention: Pessary
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 446
Study: 18626299

Group type: EXPERIMENTAL
Intervention: ACE therapy in addition to treatment as usual
Number of subjects: 24

Group type: COMPARATOR
Intervention: Supportive therapy in addition to treatment as usual
Number of subjects: 24
Study: 17472487

Group type: EXPERIMENTAL
Intervention: Elixir composed with air-dried C. papaya seeds and honey (CPH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Honey alone (placebo)
Number of subjects: 60
Study: 14679383

Group type: EXPERIMENTAL
Intervention: 1-month isoflavone supplementation (86 mg/day red clover-derived isoflavones)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10783653

Group type: EXPERIMENTAL
Intervention: Aerosolized prostaglandin (PG)I2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled NO
Number of subjects: 8

Group type: COMPARATOR
Intervention: Intravenous PGI2
Number of subjects: 8

Group type: COMPARATOR
Intervention: Systemic calcium antagonists (CAAs)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Long-term therapy with aerosolized iloprost
Number of subjects: 8
Study: 9289326

Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring spirometric parameters
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring FVC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring FEV1
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 7 observers (pneumologists) measuring FEV1/FVC
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Standardization session for spirometric measurements
Number of subjects: 21
Study: 8439095

Group type: EXPERIMENTAL
Intervention: Folic acid treatment for children with serum FA levels lower than 3 ng/ml
Number of subjects: 110

Group type: COMPARATOR
Intervention: Anticonvulsant therapy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 110
Study: 3531452

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of gentamicin
Number of subjects: 19

Group type: COMPARATOR
Intervention: Multiple-dose therapy of gentamicin
Number of subjects: 19
Study: 31960099

Group type: EXPERIMENTAL
Intervention: Screening for high hip fracture risk (FRAX)
Number of subjects: 12483

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 12483
Study: 30884079

Group type: EXPERIMENTAL
Intervention: CNI-free immunosuppression with everolimus (EVR), mycophenolic acid and steroids
Number of subjects: 145

Group type: COMPARATOR
Intervention: Reduced-exposure CNI with EVR and steroids
Number of subjects: 145
Study: 27859286

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional swallowing exercise (TE)
Number of subjects: 140
Study: 25336575

Group type: EXPERIMENTAL
Intervention: Topical brinzolamide (Azopt)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 23605805

Group type: EXPERIMENTAL
Intervention: Sublingual 10 mg Promptol™
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral Inderal(®)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sublingual 40 mg Promptol™
Number of subjects: 18
Study: 21698103

Group type: EXPERIMENTAL
Intervention: TB-specific leaflet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control leaflet providing information on mental health
Number of subjects: 0
Study: 19901236

Group type: EXPERIMENTAL
Intervention: COSA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 44
Study: 16290817

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy combined with vestibular rehabilitation (VR) program including psychoeducation, vestibular exercises, relaxation, and cognitive interventions.
Number of subjects: 29

Group type: COMPARATOR
Intervention: Waiting list control group.
Number of subjects: 29
Study: 12628840

Group type: EXPERIMENTAL
Intervention: Continuation of CMF treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 204
Study: 10692092

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with sequential transdermal 17beta‐oestradiol for 14 weeks and then medroxyprogesterone (MPA) for 14 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 99
Study: 9348452

Group type: EXPERIMENTAL
Intervention: Ethyl‐6‐O‐decanoyl‐glucoside 0.005% combined with 0.00025% chlorhexidine acetate (EDGC)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Commercial polyaminpropylbiguanide (PAPB)
Number of subjects: 59
Study: 8406404

Group type: EXPERIMENTAL
Intervention: Sublingual morphine sulfate (10 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral morphine sulfate (10 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intramuscular morphine sulfate (10 mg)
Number of subjects: 6
Study: 3088973

Group type: EXPERIMENTAL
Intervention: D‐alpha‐tocopherol (268 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DL‐alpha‐tocopherol (364 mg)
Number of subjects: 16
Study: 30041978

Group type: EXPERIMENTAL
Intervention: Geriatric Assessment (GA)
Number of subjects: 61
Study: 30411137

Group type: EXPERIMENTAL
Intervention: Nationwide skin cancer screening program
Number of subjects: 0

Group type: COMPARATOR
Intervention: SCREEN project (pilot study)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current nationwide skin cancer screening
Number of subjects: 0
Study: 27128665

Group type: EXPERIMENTAL
Intervention: Endurance exercise (EE) at 70% of V˙O2peak
Number of subjects: 9

Group type: COMPARATOR
Intervention: Blood flow restriction endurance exercise (BFR‐EE) at 40% of V˙O2peak
Number of subjects: 9

Group type: COMPARATOR
Intervention: Resistance exercise at 70% of one-repetition maximum
Number of subjects: 9
Study: 24448650

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 17

Group type: COMPARATOR
Intervention: Continuous aerobic exercise training
Number of subjects: 17
Study: 22442962

Group type: EXPERIMENTAL
Intervention: Antihypoxant reamberin included in intensive treatment
Number of subjects: 0
Study: 20096128

Group type: EXPERIMENTAL
Intervention: Hand sanitisers and an education session on hand hygiene
Number of subjects: 3400

Group type: COMPARATOR
Intervention: Education session on hand hygiene alone
Number of subjects: 3400
Study: 17394707

Group type: EXPERIMENTAL
Intervention: Tissue glue (Dermabond, Ethicon, UK)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Tissue glue
Number of subjects: 29
Study: 16275432

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 182

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 182
Study: 11568553

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg intravenously
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study: 9676667

Group type: EXPERIMENTAL
Intervention: Blinded reviewers (groups 1 and 2)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Unblinded reviewers (groups 3 and 4)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (group 5)
Number of subjects: 420
Study: 7933233

Group type: EXPERIMENTAL
Intervention: Expectant management (no treatment)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Hormonal treatment (orchiectomy or estrogens)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Deferred treatment and radical prostatectomy
Number of subjects: 223
Study: 3283629

Group type: EXPERIMENTAL
Intervention: Vindesine-mitoxantrone (VM)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Vindesine-4'-epidoxorubicin (VE)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 182
Study: 31290763

Group type: EXPERIMENTAL
Intervention: Resection of cavity shave margins (CSM)
Number of subjects: 396

Group type: COMPARATOR
Intervention: No resection of cavity shave margins (no shave)
Number of subjects: 396
Study: 31647577

Group type: EXPERIMENTAL
Intervention: 120 mg DFN-15
Number of subjects: 622
Study: 29683391

Group type: EXPERIMENTAL
Intervention: Grape Seed Extract (GSE) 300 mg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 26979136

Group type: EXPERIMENTAL
Intervention: AV7909 on Days 0/14
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: AV7909 on Days 0/28
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: AV7909 on Days 0/14/28
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: half dose AV7909 on Days 0/14/28
Number of subjects: 168

Group type: COMPARATOR
Intervention: BioThrax vaccine on Days 0/14/28
Number of subjects: 168
Study: 25494177

Group type: EXPERIMENTAL
Intervention: Subcutaneous fat suture closure
Number of subjects: 116

Group type: COMPARATOR
Intervention: Non-closure
Number of subjects: 116
Study: 22209361

Group type: EXPERIMENTAL
Intervention: Lu AA21004 5 mg
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Lu AA21004 10 mg
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Lu AA21004 2.5 mg
Number of subjects: 766

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study: 20177281

Group type: EXPERIMENTAL
Intervention: Acupuncture specific for depression
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control acupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Massage
Number of subjects: 150
Study: 17982558

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture (EAC)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24
Study: 16125515

Group type: EXPERIMENTAL
Intervention: 15-week rehabilitation program including individual exercise, sports, psycho-education, and information
Number of subjects: 63
Study: 12137819

Group type: EXPERIMENTAL
Intervention: Urethral dilation with Benique dilatators (maximal 21F) under intraurethral anesthesia, starting 10 days after initial DVIU, protocol: weekly for the first month, once after 3 and 6 months, then annually.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Consecutive DVIUs considered when stricture recurred after initial DVIU.
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Maximal urinary flow rate at last follow-up.
Number of subjects: 37
Study: 10655186

Group type: EXPERIMENTAL
Intervention: Sodium diclofenac 0.1% drops
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% drops
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Sodium diclofenac 0.1% drops and Sodium chloride 0.9% drops
Number of subjects: 87
Study: 8653256

Group type: EXPERIMENTAL
Intervention: Nurse First (NF)
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Doctor First (DF)
Number of subjects: 2000
Study: 1944438

Group type: EXPERIMENTAL
Intervention: Acyclovir (20 mg/kg, orally, four times daily for five days)
Number of subjects: 815

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 815

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study: 6686118

Group type: EXPERIMENTAL
Intervention: beta-blockade (50 mg oral metoprolol or 40 mg oral propranolol, each twice per day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: beta-blockade (metoprolol)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: beta-blockade (propranolol)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: beta-blockade
Number of subjects: 17
Study: 31797987

Group type: EXPERIMENTAL
Intervention: Antenatal micronutrient supplementation
Number of subjects: 1388
Study: 28107273

Group type: EXPERIMENTAL
Intervention: BIS 55
Number of subjects: 12

Group type: COMPARATOR
Intervention: BIS 25
Number of subjects: 12
Study: 26628417

Group type: EXPERIMENTAL
Intervention: Pregnant participants (n=63 pregnancies)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Pregnant participants (n=53 pregnancies)
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Live-born infants (n=39)
Number of subjects: 452
Study: 25136625

Group type: EXPERIMENTAL
Intervention: Butter-based breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Margarine-based breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olive oil-based breakfast
Number of subjects: 0

Group type: COMPARATOR
Intervention: All breakfast types
Number of subjects: 0
Study: 23160696

Group type: EXPERIMENTAL
Intervention: 7.5 mg/ml ropivacaine (group A, 42 patients)
Number of subjects: 86

Group type: COMPARATOR
Intervention: 5 mg/ml levobupivacaine (group B, 44 patients)
Number of subjects: 86
Study: 19465290

Group type: EXPERIMENTAL
Intervention: 3‐piece AcrySof MA60BM IOL implanted in the capsular bag
Number of subjects: 14

Group type: COMPARATOR
Intervention: 3‐piece AcrySof MA60BM IOL implanted in the ciliary sulcus with optic captured through PCCC
Number of subjects: 14
Study: 17469891

Group type: EXPERIMENTAL
Intervention: Education and acceptance and commitment therapy (ACT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 81
Study: 15660859

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation 4 mg/kg per day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no oral iron supplementation)
Number of subjects: 24
Study: 10782187

Group type: EXPERIMENTAL
Intervention: Hearing Loss Prevention Program (HLPP)
Number of subjects: 44547
Study: 9058176

Group type: EXPERIMENTAL
Intervention: Support availability condition
Number of subjects: 49

Group type: COMPARATOR
Intervention: No support availability condition
Number of subjects: 49
Study: 8367728

Group type: EXPERIMENTAL
Intervention: Multiple trauma rehabilitation
Number of subjects: 104
Study: 3094411

Group type: EXPERIMENTAL
Intervention: 40 mg cromolyn
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study: 3177551

Group type: EXPERIMENTAL
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Genetic amniocentesis
Number of subjects: 0
Study: 31526014

Group type: EXPERIMENTAL
Intervention: Low-dose CT (0.8 mSv)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard-dose CT (4.2 mSv)
Number of subjects: 19
Study: 31405924

Group type: EXPERIMENTAL
Intervention: 400mg amisulpride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40mg propranolol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28532881

Group type: EXPERIMENTAL
Intervention: Diaphragm Release
Number of subjects: 17
Study: 25492246

Group type: EXPERIMENTAL
Intervention: Triathlon CS TKA
Number of subjects: 31

Group type: COMPARATOR
Intervention: Triathlon PS TKA
Number of subjects: 31
Study: 23009193

Group type: EXPERIMENTAL
Intervention: Cerebrolysin plus alteplase
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 21667089

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study: 18088241

Group type: EXPERIMENTAL
Intervention: Lamivudine for 52 weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lamivudine for at least 2 years
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lamivudine (previous treatment)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 151
Study: 17070256

Group type: EXPERIMENTAL
Intervention: Pre-shock wave lithotripsy 6Fr Double-J stent
Number of subjects: 186

Group type: COMPARATOR
Intervention: No stent
Number of subjects: 186
Study: 15172892

Group type: EXPERIMENTAL
Intervention: Rifampin for 4 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Isoniazid for 9 months
Number of subjects: 58
Study: 11026174

Group type: EXPERIMENTAL
Intervention: Information about suicide risk and urging to remove guns from the home
Number of subjects: 106

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 106
Study: 9315793

Group type: EXPERIMENTAL
Intervention: NPPV during NREM sleep
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: NPPV during REM sleep
Number of subjects: 6

Group type: COMPARATOR
Intervention: NPPV vs control-sham on sleep efficiency
Number of subjects: 6

Group type: COMPARATOR
Intervention: NPPV vs control-sham on total sleep time (TST)
Number of subjects: 6

Group type: COMPARATOR
Intervention: NPPV vs control-sham on sleep architecture
Number of subjects: 6

Group type: COMPARATOR
Intervention: NPPV vs control-sham on number of arousals
Number of subjects: 6
Study: 8113478

Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy (PST)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Reminiscence Therapy (RT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waiting-List Control (WLC)
Number of subjects: 75
Study: 3750071

Group type: EXPERIMENTAL
Intervention: Knodt Rods
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Knodt Rods (Control)
Number of subjects: 24
Study: 30993928

Group type: EXPERIMENTAL
Intervention: Endovascular intervention treatment
Number of subjects: 23
Study: 28924412

Group type: EXPERIMENTAL
Intervention: Video Magnifier (VM) added to standard vision rehabilitation (VR)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard vision rehabilitation (VR)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both groups (VM and VR)
Number of subjects: 37
Study: 26320858

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 23515115

Group type: EXPERIMENTAL
Intervention: web-based stroke education program
Number of subjects: 36

Group type: COMPARATOR
Intervention: control group
Number of subjects: 36
Study: 21196761

Group type: EXPERIMENTAL
Intervention: Birch pollen honey (BPH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Regular honey (RH)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (usual allergy medication)
Number of subjects: 44
Study: 18070004

Group type: EXPERIMENTAL
Intervention: Melatonin (5 mg) and bright-light therapy (1 hour of morning light exposure at > or = 2,500 lux)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual indoor light (150-200 lux)
Number of subjects: 50
Study: 16527014

Group type: EXPERIMENTAL
Intervention: Oxymetazoline nasal spray (0.05% concentration, one spray in each nostril, three times a day for 5 days)
Number of subjects: 60
Study: 12866606

Group type: EXPERIMENTAL
Intervention: CI‐1023 (Ad(GV)VEGF121.10), a replication‐deficient adenovirus encoding human vascular endothelial growth factor isoform 121, administered via intramuscular injection (4 x 10(8) to 4 x 10(10) particle units)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 11324805

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Cilostazol
Number of subjects: 35
Study: 9340057

Group type: COMPARATOR
Intervention: Chemotherapy (Carboplatine, Etoposide, Vincristine, 6 courses, 3-week basis)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (same chemotherapy regimen + primary site irradiation, total dose 40Gy)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 62
Study: 8349471

Group type: EXPERIMENTAL
Intervention: Piroxicam FDDF (40 mg in a single sublingual dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2882966

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (1000 mg, Pentasa)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Prednisolone (25 mg)
Number of subjects: 123
Study: 29691246

Group type: EXPERIMENTAL
Intervention: BetterBack model of care (MOC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current routine care
Number of subjects: 0
Study: 28716522

Group type: EXPERIMENTAL
Intervention: Aerobic interval training (AIT) individualized by TRIMPi method
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care (SOC)
Number of subjects: 22